The global Circulating Tumor Cells market size is expected to be worth around US$ 20.3 billion by 2030, according to a new report by Vision Research Reports.
The global Circulating Tumor Cells market size was valued at US$ 10.4 billion in 2020 and is anticipated to grow at a CAGR of 15.7% during forecast period 2021 to 2030.
Growth Factors
Many potential applications of CTCs in pre-diagnosis, pretreatment, and intra- and post-treatment provide lucrative growth opportunities to players involved in the development of CTC enrichment and isolation products Research organizations are engaged in endeavors aimed at developing CTC-based tests to improve cancer diagnosis in terms of efficiency and speed.
Furthermore, the growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. CTC-based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.
Report Highlights
The CTC detection and enrichment methods segment accounted for the largest revenue share of 75.8%. The availability of different methods for the enrichment of circulating tumor cells in cancer detection is expected to significantly impact segment growth over the forecast period. Moreover, positive or negative enrichment of circulating tumor cells based on biological properties is expected to hold significant potential for market growth.
An effective enrichment process helps in the enhancement of sensitivity, selectivity, and yield, thereby ensuring successful clinical translation of this field. Different detection techniques include magnetic beads-based enrichment, centrifugal force, filtration, and other physical properties such as size, density, deformity, and electric charges.
Advancements in technologies such as immunofluorescence, NGS, FISH, and qPCR are anticipated to drive the clinical utility of these cells, and thus accelerating revenue growth for CTC analyses. Several companies are investing in the development of products that help in CTC analysis and downstream assays. For instance, Vortex Biosciences offers various CTC analysis products, including immunofluorescence, cytopathology, cytogenetics (FISH), cell culture, and genomics.
The research segment dominated the market and captured the largest revenue share of 82.8% in 2020. Circulating tumor cells are regarded as a substrate of cancer metastasis. Circulating tumor cells enumeration remains largely a research tool. Recently, the focus has shifted toward circulating tumor cells characterization and isolation, which can provide significant opportunities in predictive testing research.
This arena has significantly improved cancer studies, thus, products offered in the market are primarily designed to be used within research settings. Some key products that have contributed to the large share of research settings are Parsortix Technology, Target Selector Platform, Apostream, Celsee PREP 400, IsoFlux CTC system, DEPArray System, VTX-1, and AdnaTest.
The devices or systems segment dominated the market and accounted for the largest revenue share of 52.8% in 2020. This can be attributed to the presence of a wide portfolio under this category coupled with upcoming advances with regard to microfluidics technology. The introduction of fabricated glass microchips to overcome the challenges and to increase technical completeness for mass production are expected to propel further growth in this segment.
The development of automated instruments that eliminates the use of additional blood collection tubes hampers the revenue growth of blood collection tubes. The reduction in costs is also observed as the transportation is free of the additional laboratory consumables and transfer tubes when the reagent-equipped tubes are used.
The blood specimen segment dominated the market and accounted for the largest revenue share of 56.9% in 2020. A large concentration of these cells in blood samples as compared with other biospecimens is responsible for the largest penetration of this specimen type. Approaches for tumor cells identification in blood samples is considered important in current cancer research, as it aids in the prediction of prognosis and determination of the response to systemic chemotherapy. However, the use of whole blood as a specimen poses a challenge when combined with microfluidic technology.
Membrane clogging as a result of a high concentration of blood cells minimizes the applicability of whole blood samples in microfluidic-based circulating tumor cells enumeration. Devices with various pore shapes and sizes are anticipated to overcome this issue and drive segment growth in the coming years. Moreover, the development of fluid-assisted separation technology by Clinomics, a molecular laboratory based in Bloemfontein, Free State can be employed for efficient detection of these cells.
In 2020, North America dominated the Circulating Tumor Cells (CTCs) market and accounted for the largest revenue share of 61.2%. Advanced Cell Diagnostics; Apocell, Inc.; Aviva Biosciences; Biocept, Inc.; Biofluidica, Inc.; and CellTraffix, Inc are the key players operating in the region. These players are undertaking various strategies to enhance their market hold can be attributed to the large share of the U.S. market.
Furthermore, the presence of a population with high susceptibility to cancer, an increase in market penetration rates, and technologically advanced cancer care infrastructure are some of the key factors accounting for its large share. On the other hand, Asia Pacific is projected to grow at a lucrative rate due to high unmet diagnostic needs coupled with rapidly growing patient awareness with regard to early detection of cancer and risk assessment.
Report Coverage | Details |
Market Size | US$ 20.3 billion by 2030 |
Growth Rate | CAGR of 15.7% From 2021 to 2030 |
Base year | 2020 |
Historic Data | 2017 to 2020 |
Forecast Period | 2021 to 2030 |
Segments Covered | Technology, Application, Product, Specimen |
Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA) |
Companies Mentioned | QIAGEN; Bio-Techne Corporation; Precision for Medicine; AVIVA Biosciences; BIOCEPT, Inc.; BioCEP Ltd.; Fluxion Biosciences, Inc.; Greiner Bio One International GmbH; Ikonisys Inc.; Miltenyi Biotec; IVDiagnostics; BioFluidica; Canopus Bioscience Ltd.; Biolidics Limited; Creativ MicroTech, Inc.; LungLife AI, Inc.; Epic Sciences; Rarecells Diagnostics; ScreenCell; Menarini Silicon Biosystems; LineaRx, Inc. (Vitatex, Inc.); Sysmex Corporation; STEMCELL Technologies, Inc. |
Key Players
QIAGEN
Bio-Techne Corporation
Precision for Medicine
AVIVA Biosciences
BIOCEPT, Inc.
BioCEP Ltd.
Fluxion Biosciences, Inc.
Greiner Bio One International GmbH
Ikonisys Inc.
Miltenyi Biotec
IVDiagnostics
BioFluidica
Canopus Bioscience Ltd.
Biolidics Limited
Creativ MicroTech, Inc.
LungLife AI, Inc.
Epic Sciences
Rarecells Diagnostics
ScreenCell
Menarini Silicon Biosystems
LineaRx, Inc. (Vitatex, Inc.)
Sysmex Corporation
STEMCELL Technologies, Inc.
Market Segmentation
Technology Outlook
CTC Detection & Enrichment Methods
Immunocapture (Label-based)
Positive Selection
Negative Selection
Size-based Separation (Label-free)
Membrane-based
Microfluidic-based
Density-based Separation (Label-free)
Combined Methods (Label-free)
CTC Direct Detection Methods
SERS
Microscopy
Others
CTC Analysis
Application Outlook
Clinical/ Liquid Biopsy
Risk Assessment
Screening and Monitoring
Research
Cancer Stem Cell & Tumorogenesis Research
Drug/Therapy Development
Product Outlook
Kits & Reagents
Blood Collection Tubes
Devices or Systems
Specimen Outlook
Blood
Bone Marrow
Other Body Fluids
Regional Outlook
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Asia Pacific
China
Japan
India
South Korea
Singapore
Australia
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
UAE
The Circulating Tumor Cells market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Circulating Tumor Cells market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Circulating Tumor Cells market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Circulating Tumor Cells market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Circulating Tumor Cells market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Circulating Tumor Cells capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Circulating Tumor Cells by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Circulating Tumor Cells market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Circulating Tumor Cells market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Circulating Tumor Cells market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Circulating Tumor Cells industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Circulating Tumor Cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Circulating Tumor Cells market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Circulating Tumor Cells market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Circulating Tumor Cells market. These factors have benefited the growth of the global market for Circulating Tumor Cells. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Circulating Tumor Cells. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Circulating Tumor Cells are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Circulating Tumor Cells Market, By Technology
7.1. Circulating Tumor Cells Market, by Technology, 2020-2030
7.1.1. CTC Detection & Enrichment Methods
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. CTC Direct Detection Methods
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. CTC Analysis
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Circulating Tumor Cells Market, By Application
8.1. Circulating Tumor Cells Market, by Application, 2020-2030
8.1.1. Clinical/ Liquid Biopsy
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Research
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Circulating Tumor Cells Market, By Product
9.1. Circulating Tumor Cells Market, by Product, 2020-2030
9.1.1. Kits & Reagents
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Blood Collection Tubes
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Devices or Systems
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Circulating Tumor Cells Market, By Specimen
10.1. Circulating Tumor Cells Market, by Specimen, 2020-2030
10.1.1. Blood
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast (2016-2030)
10.1.3. Other Body Fluids
10.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 11. Global Circulating Tumor Cells Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.1.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.1.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.1.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.2.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.2.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.2.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.3.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.3.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.3.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.7.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.7.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Technology (2016-2030)
11.4.8.2. Market Revenue and Forecast, by Application (2016-2030)
11.4.8.3. Market Revenue and Forecast, by Product (2016-2030)
11.4.8.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.5.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.5.4. Market Revenue and Forecast, by Specimen (2016-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Technology (2016-2030)
11.5.6.2. Market Revenue and Forecast, by Application (2016-2030)
11.5.6.3. Market Revenue and Forecast, by Product (2016-2030)
11.5.6.4. Market Revenue and Forecast, by Specimen (2016-2030)
Chapter 12. Company Profiles
12.1. QIAGEN
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bio-Techne Corporation
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Precision for Medicine
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AVIVA Biosciences
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BIOCEPT, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. BioCEP Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Fluxion Biosciences, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Greiner Bio One International GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Ikonisys Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Miltenyi Biotec
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. IVDiagnostics
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. BioFluidica
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
12.13. Canopus Bioscience Ltd.
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance
12.13.4. Recent Initiatives
12.14. Biolidics Limited
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance
12.14.4. Recent Initiatives
12.15. Creativ MicroTech, Inc.
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance
12.15.4. Recent Initiatives
12.16. LungLife AI, Inc.
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance
12.16.4. Recent Initiatives
12.17. Epic Sciences
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance
12.17.4. Recent Initiatives
12.18. Rarecells Diagnostics
12.18.1. Company Overview
12.18.2. Product Offerings
12.18.3. Financial Performance
12.18.4. Recent Initiatives
12.19. ScreenCell
12.19.1. Company Overview
12.19.2. Product Offerings
12.19.3. Financial Performance
12.19.4. Recent Initiatives
12.20. Menarini Silicon Biosystems
12.20.1. Company Overview
12.20.2. Product Offerings
12.20.3. Financial Performance
12.20.4. Recent Initiatives
12.21. LineaRx, Inc. (Vitatex, Inc.)
12.21.1. Company Overview
12.21.2. Product Offerings
12.21.3. Financial Performance
12.21.4. Recent Initiatives
12.22. Sysmex Corporation
12.22.1. Company Overview
12.22.2. Product Offerings
12.22.3. Financial Performance
12.22.4. Recent Initiatives
12.23. STEMCELL Technologies, Inc.
12.23.1. Company Overview
12.23.2. Product Offerings
12.23.3. Financial Performance
12.23.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
Glossary of Terms